Akihiko Yoshida

Summary

Affiliation: University of Tokyo
Country: Japan

Publications

  1. ncbi Soft-tissue hemangioblastoma of the retroperitoneum: a case study and review of the literature
    Akihiko Yoshida
    Clinical Laboratory Division, National Cancer Center Hospital, University of Tokyo, Tokyo, Japan
    Appl Immunohistochem Mol Morphol 18:479-82. 2010
  2. ncbi Immunohistochemical analysis of MDM2 and CDK4 distinguishes low-grade osteosarcoma from benign mimics
    Akihiko Yoshida
    Clinical Laboratory Division, National Cancer Center Hospital, Tokyo, Japan
    Mod Pathol 23:1279-88. 2010
  3. ncbi Well-differentiated liposarcoma with low-grade osteosarcomatous component: an underrecognized variant
    Akihiko Yoshida
    Clinical Laboratory Division, National Cancer Center Hospital, Tokyo, Japan
    Am J Surg Pathol 34:1361-6. 2010
  4. ncbi c-MET/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas
    Koji Tsuta
    Division of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan
    J Thorac Oncol 7:331-9. 2012
  5. ncbi Bright-field dual-color chromogenic in situ hybridization for diagnosing echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinomas
    Akihiko Yoshida
    Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Japan
    J Thorac Oncol 6:1677-86. 2011
  6. ncbi Comprehensive histologic analysis of ALK-rearranged lung carcinomas
    Akihiko Yoshida
    Pathology and Clinical Laboratory Division, National Cancer Center Hospital, Tokyo, Japan
    Am J Surg Pathol 35:1226-34. 2011
  7. ncbi MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma: correlation with a dedifferentiated subtype
    Akihiko Yoshida
    Departments of Pathology and Clinical Laboratories, National Cancer Center Research Institute, Tokyo, Japan
    Am J Surg Pathol 36:423-31. 2012
  8. ncbi Utility of 10 immunohistochemical markers including novel markers (desmocollin-3, glypican 3, S100A2, S100A7, and Sox-2) for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the Lung
    Koji Tsuta
    Division of Pathology and Clinical Laboratory, National Cancer Center Hospital, Tokyo, Japan
    J Thorac Oncol 6:1190-9. 2011
  9. ncbi NKX2.2 is a useful immunohistochemical marker for Ewing sarcoma
    Akihiko Yoshida
    Pathology and Clinical Laboratory Division, National Cancer Center Hospital, Tokyo, Japan
    Am J Surg Pathol 36:993-9. 2012
  10. ncbi Steroid receptor expression in thymomas and thymic carcinomas
    Takahiro Mimae
    Pathology and Clinical Laboratory Division, National Cancer Center Hospital, Tokyo, Japan
    Cancer 117:4396-405. 2011

Detail Information

Publications15

  1. ncbi Soft-tissue hemangioblastoma of the retroperitoneum: a case study and review of the literature
    Akihiko Yoshida
    Clinical Laboratory Division, National Cancer Center Hospital, University of Tokyo, Tokyo, Japan
    Appl Immunohistochem Mol Morphol 18:479-82. 2010
    ..The patient is well 4 years after the surgery without any recurrence. A review of the literature revealed that soft-tissue hemangioblastoma is typically a solid tumor found in older females and often involves the retroperitoneum/pelvis...
  2. ncbi Immunohistochemical analysis of MDM2 and CDK4 distinguishes low-grade osteosarcoma from benign mimics
    Akihiko Yoshida
    Clinical Laboratory Division, National Cancer Center Hospital, Tokyo, Japan
    Mod Pathol 23:1279-88. 2010
    ..MDM2 and CDK4 immunostains therefore reliably distinguish low-grade osteosarcoma from benign histological mimics, and their combination may serve as a useful adjunct in this difficult differential diagnosis...
  3. ncbi Well-differentiated liposarcoma with low-grade osteosarcomatous component: an underrecognized variant
    Akihiko Yoshida
    Clinical Laboratory Division, National Cancer Center Hospital, Tokyo, Japan
    Am J Surg Pathol 34:1361-6. 2010
    ....
  4. ncbi c-MET/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas
    Koji Tsuta
    Division of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan
    J Thorac Oncol 7:331-9. 2012
    ..The aim of this study was to examine the correlations between c-MET/phospho-MET expression as well as MET gene copy number alterations and overall survival (OS) in non-small cell lung carcinomas (NSCLCs)...
  5. ncbi Bright-field dual-color chromogenic in situ hybridization for diagnosing echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinomas
    Akihiko Yoshida
    Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Japan
    J Thorac Oncol 6:1677-86. 2011
    ..In this study, we explored the potential of the ALK-break-apart chromogenic in situ hybridization (CISH) method to detect ALK-rearranged lung cancer...
  6. ncbi Comprehensive histologic analysis of ALK-rearranged lung carcinomas
    Akihiko Yoshida
    Pathology and Clinical Laboratory Division, National Cancer Center Hospital, Tokyo, Japan
    Am J Surg Pathol 35:1226-34. 2011
    ..ALK-positive cancers commonly showed coexpression of thyroid transcription factor-1 and p63, and its significance is currently unclear...
  7. ncbi MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma: correlation with a dedifferentiated subtype
    Akihiko Yoshida
    Departments of Pathology and Clinical Laboratories, National Cancer Center Research Institute, Tokyo, Japan
    Am J Surg Pathol 36:423-31. 2012
    ....
  8. ncbi Utility of 10 immunohistochemical markers including novel markers (desmocollin-3, glypican 3, S100A2, S100A7, and Sox-2) for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the Lung
    Koji Tsuta
    Division of Pathology and Clinical Laboratory, National Cancer Center Hospital, Tokyo, Japan
    J Thorac Oncol 6:1190-9. 2011
    ..Recent clinical trials revealed that accurate histologic typing of non-small cell lung cancer, especially squamous cell carcinoma (SCC), is essential...
  9. ncbi NKX2.2 is a useful immunohistochemical marker for Ewing sarcoma
    Akihiko Yoshida
    Pathology and Clinical Laboratory Division, National Cancer Center Hospital, Tokyo, Japan
    Am J Surg Pathol 36:993-9. 2012
    ..All the other non-Ewing tumors tested were negative for this marker. NKX2.2 is a valuable marker for Ewing sarcoma, with a sensitivity of 93% and a specificity of 89%, and aids in the differential diagnosis of small round cell tumors...
  10. ncbi Steroid receptor expression in thymomas and thymic carcinomas
    Takahiro Mimae
    Pathology and Clinical Laboratory Division, National Cancer Center Hospital, Tokyo, Japan
    Cancer 117:4396-405. 2011
    ....
  11. ncbi Extraskeletal myxoid chondrosarcoma: a review of 23 patients treated at a single referral center with long-term follow-up
    Koichi Ogura
    Division of Musculoskeletal Oncology, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Arch Orthop Trauma Surg 132:1379-86. 2012
    ..The aim of this study was to clarify the long-term clinical features of EMC treated at a single referral center using state-of-the-art techniques...
  12. ncbi The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma
    Yoshiki Kozu
    Division of Clinical Laboratory, National Cancer Center Hospital, Tokyo, Japan
    Lung Cancer 73:45-50. 2011
    ..The ability to detecting such mutations using immunohistochemistry (IHC) would be advantageous...
  13. ncbi Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component
    Akihiko Yoshida
    Clinical Laboratory Division, National Cancer Center Hospital, Japan
    Lung Cancer 72:309-15. 2011
    ..The characteristic histology, immunoprofile, frequent ALK translocation, and total lack of EGFR or KRAS mutations, may suggest that Ad-SRCC forms a histologically/molecularly coherent subgroup of adenocarcinoma...
  14. ncbi Validation study on pfetin and ATP-dependent RNA helicase DDX39 as prognostic biomarkers in gastrointestinal stromal tumour
    Daisuke Kubota
    Division of Pharmacoproteomics, National Cancer Center Research Institute, Tokyo, Japan
    Jpn J Clin Oncol 42:730-41. 2012
    ..Prognostic biomarkers have long been required for the optimal use of kinase inhibitors in gastrointestinal stromal tumour...
  15. ncbi Alveolar soft part sarcoma: a single-center 26-patient case series and review of the literature
    Koichi Ogura
    Division of Musculoskeletal Oncology, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Sarcoma 2012:907179. 2012
    ..Conclusions. ASPS is indolent but has a high propensity for metastasis. Early diagnosis and complete excision of the small primary tumor are essential in the treatment of ASPS...